Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2015, vol. 21, issue 1
Subject Area: Medicine
Pages: 722-727
DOI: 10.5272/jimab.2015211.722
Published online:19 March 2015

J of IMAB 2015 Jan-Mar;21(1):722-727
Tatjana JakovskaCorresponding Autor, Stojka Fustik, Tatjana Zorcec.
Department of cystic fibrosis, metabolism and psychophysiology, University Pediatric Clinic, Medical Faculty, Cyril and Methodius University, Skopje, Macedonia.

Introduction: failure to maintain bone mass density is a major problem in patients with cystic fibrosis (CF). CF is due to mutations in the CFTR gene and other genes may contribute to modifying the disease. Genetic and environmental factors may play a role in determining the variability of bone mass.
Aim of the study:
to analyse the association between polymorphic variants of genes considered to be risk factors of bone metabolism disturbances and decreased bone mineral density (BMD) in children and adults with CF in R. Macedonia.
Materials and methods: the study included 80 clinically stable CF patients (age range 5-36y), who regularly attended the CF center at the Pediatric Clinic in Skopje, Macedonia. Three candidate genes likely associated with BMD variability were studied: the vitamin D receptor (VDR) gene, the estrogen receptor alpha (ESR1) and the type I alpha I collagen (COLIA1) gene. A complete bone and CF evaluation was obtained for all patients: 55 had normal BMD (group 1), 17 were osteopenic (group 2) and 8 were osteoporotic (group 3).
Low bone mineral density (Z score < -1SD) was found in 31.25% patients and in 10% of them BMD was below -2SD. Patients with low BMD had worse BMI, FEV1 and more severe symptoms of CF. No significant correlation was found between COLIA1 and VDR polymorphisms and BMD.
Conclusion: There was no evidence that the genes under study may modulate bone phenotype in CF.

Key words: cystic fibrosis, osteoporosis, modifier genes,

- Download FULL TEXT /PDF 687 KB/
Please cite this article in PubMed Style or AMA (American Medical Association) Style:
Jakovska T, Fustik S, Zorcec T. Genetic markers of low bone mineral density in patients with cystic fibrosis. J of IMAB. 2015 Jan-Mar;21(1):722-727. doi:

Correspondence to: Tatjana Jakovska, MD, PhD, Vodnjanska 17, 1000 Skopje, Macedonia; E-mail:; and Tatjana Zorcec, MD, E-mail:

1. Buzzetti R, Salvatore D, Baldo E, Forneris MP, Lucidi V, Manunza D, et al. An overview of international literature from cystic fibrosis registries: Mortality and survival studies in cystic fibrosis. J Cyst Fibros. 2009 Jul;8(4):229–237. [CrossRef] [PubMed]
2. Javier RM, Jacquot J. Bone disease in cystic fibrosis: what’s new? Joint Bone Spine. 2011 Oct;78(5):445-50. [CrossRef] [PubMed]
3. Mischler EH, Chesney PJ, Chesney RW, Mazess RB. Demineralization in cystic fibrosis detected by direct photon absorptiometry. Am J Dis Child. 1979 Jun;133:632-635. [PubMed]
4. Paccou J, Zeboulon N, Combescure C, Gossec L, Cortet B. The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis. Calcif Tissue Int. 2010 Jan;86(1):1–7. [PubMed] [CrossRef]
5. Aris RM, Merkel PA, Bachrach LK, Borowitz DS, Boyle MP, Elkin SL, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab. 2005 Mar;90(3):1888–96. [PubMed] [CrossRef]
6. Elkin SL, Fairney A, Burnett S, Kemp M, Kyd P, Burgess J, et al. Vertebral deformities and low bone mineral density in adults with cystic fibrosis: a cross-sectional study. Osteoporos Int. 2001; 12(5):366–72. [PubMed] [CrossRef]
7. Sermet-Gaudelus I, Souberbielle JC, Ruiz JC, Vrielynck S, Heuillon B, Azhar I, et al. Low bone mineral density in young children with cystic fibrosis. Am J Respir Crit Care Med. 2007 May;175(9):951–7. [PubMed] [CrossRef]
8. Stephenson A, Jamal S, Dowdell T, Pearce D, Corey M, Tullis E. Prevalence of vertebral fractures in adults with cystic fibrosis and their relationship to bone mineral density. Chest. 2006 Aug;130(2):539–44. [PubMed] [CrossRef]
9. Buntain HM, Greer RM, Schluter PJ, Wong JC, Batch JA, Potter JM. Bone mineral density in Australian children, adolescents and adults with cystic fibrosis: a controlled cross sectional study. Thorax. 2004 Feb;59(2):149–55. [PubMed] [CrossRef]
10. Grey V, Atkinson S, Drury D, Casey L, Ferland G, Gundberg C, et al. Prevalence of low bone mass and deficiencies of vitamins D and K in pediatric patients with cystic fibrosis from 3 Canadian centers. Pediatrics. 2008 Nov;122(5):1014–20. [PubMed] [CrossRef]
11. Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi ML, et al. International society for clinical densitometry 2007 adult and pediatric official positions. Bone. 2008 Dec;43(6):1115–1121. [PubMed] [CrossRef]
12. Rovner AJ, Stallings VA, Schall JI, Leonard MB, Zemel BS. Vitamin D insufficiency in children, adolescents, and young adults with cystic fibrosis despite routine oral supplementation. Am J Clin Nutr. 2007 Dec;86(6):1694–9. [PubMed]
13. Khazai NB, Judd SE, Jeng L, Wolfenden LL, Stecenko A, Ziegler TR, et al. Treatment and prevention of vitamin D insufficiency in cystic fibrosis patients: comparative efficacy of ergocalciferol, cholecalciferol, and UV light. J Clin Endocrinol Metab. 2009 Jun;94(6):2037–43. [PubMed] [CrossRef]
14. Hahn TJ, Squires AE, Halstead LR, Strominger DB, Reduced serum 25-hydroxyvitamin D concentration and disordered mineral metabolism in patients with cystic fibrosis. J Pediatr. 1979; 94:38-42.
15. Hall WB, Sparks AA, Aris RM. Vitamin D deficiency in cystic fibrosis. Int J Endocrinol. Vol. 2010 (2010), Article ID 218691, 9 pages. [CrossRef]
16. Castellani C, Malerba G, Sangalli A, Delmarco A, Petrelli E, Rossini M, et al. The genetic background of osteoporosis in cystic fibrosis: association analysis with polymorphic markers in four candidate genes. J Cyst Fibros. 2006 Dec;5(4):229-35. [PubMed] [CrossRef]
17. King SJ, Topliss DJ, Kotsimbos T, Nyulasi IB, Bailey M, Ebeling PR, et al. Reduced bone density in cystic fibrosis: DeltaF508 mutation is an independent risk factor. Eur Respir J. 2005 Jan;25(1):54-61. [PubMed] [CrossRef]
18. Aris RM, Guise TA. Cystic fibrosis and bone disease: are we missing a genetic link? Eur Respir J. 2005 Jan;25(1):9-11. [PubMed] [CrossRef]
19. Treszl A, Németh K, Kocsis I, Vásárhelyi B, Fekete G, Tulassay T, et al. The prevalence of DeltaF508 in primary osteoporotic patients. Eur Respir J. 2005 Aug;26(2);362-363. [PubMed] [CrossRef]
20. Norek A, Romanowska-Pietrasiak B, Bal J. [Genetic markers in the pathogenesis of osteopenia and osteoporosis in cystic fibrosis.] [in Polish] Med Wieku Rozwoj. 2006 Jan-Mar;10(1 Pt2):275-87. [PubMed]
21. He C, Kraft P, Chasman DI, Buring JE, Chen C, Hankinson SE, et al. A large-scale candidate gene association study of age at menarche and age at natural menopause. Hum Genet. 2010 Nov;128(5):515-527. [PubMed] [CrossRef]
22. Gong YG, Li YN, Zhang WH, Liu LJ, Kang XG. [Correlation between vitamin D receptor genetic polymorphism and 25-hydroxyvitamin D3 in vitamin D deficiency rickets.] [in Chinese] Zhongguo Dang Dai Er Ke Za Zhi. 2010 Jul;12(7):544-6. [PubMed]
23. Vupputuri MR, Goswami R, Gupta N, Ray D, Tandon N, Kumar N. Prevalence and functional significance of 25-hydroxyvitamin D deficientyand vitamin D receptor gene polymorphism in Asian Indians. Am J ClinNutr. 2006 Jun;83(6):1411-9. [PubMed]
24. Bhanushali AA, Lajpal N, Kulkarni SS, Chavan SS, Bagadi SS, Das BR. Frequency of fokI and taqI polymorphism of vitamin D receptor gene in Indian population and its association with 25-hydroxyvitamin D levels. Indian J Hum Genet. 2009 Sep;15(3):108-13. [PubMed] [CrossRef]

Received: 04 January 2015
Published online: 19 March 2015

back to Online Journal